Guidelines recommend: uPA/PAI-1

The urokinase type plasminogen activator (uPA) and its inhibitor (PAI-1) are clinically validated prognostic factors (1,2), which enable improved risk assessment in primary breast cancer. The prognostic impact of both factors has been confirmed using a randomised prospective trial and a pooled analysis. uPA and PAI-1 are recommended by the German AGO Guidelines and the American ASCO Clinical Guidelines 2007 as prognostic factors for therapy decision in node negative breast cancer. Determination of uPA and PAI-1 via the FEMTELLE® uPA/PAI-1 ELISA Test has been validated for clinical routine use.

The Role of FEMTELLE uPA/PAI-1 ELISA

FEMTELLE® is a clinically validated assay that predicts the likelihood of breast cancer recurrence in primary breast cancer (6,7). In addition it also assesses the benefit from chemotherapy (8).

Prospective randomized trials and a pooled analysis have confirmed that determination of uPA and PAI-1 levels in tumor tissue samples allow for improved risk assessment of the course of the disease in node-negative breast cancer patients (6,7).

Patients with node-negative breast cancer with low antigen levels of uPA and PAI-1 in their primary tumor tissue have a very good prognosis and therefore may be spared the burden of adjuvant chemotherapy, whereas those with elevated uPA/PAI-1 levels carry an increased risk of disease recurrence following surgery (6,7).

In addition, a predictive value for chemotherapy efficacy has recently been studied. High levels of uPA and PAI-1 in breast cancer are associated with a preferential response to adjuvant chemotherapy (8).

FEMTELLE® uPA/PAI-1 ELISA Test

- The FEMTELLE® uPA/PAI-1 ELISA Test enables reliable and quantitative determination of uPA and PAI-1 concentrations in tumor tissue extracts.
- uPA and PAI-1 values can be used as a prognostic indicator of high risk and low risk node-negative breast cancer patients.
- FEMTELLE™ has been validated in long term (>10 years) clinical studies in a population of more than 8000 patients.
- The test has been validated for clinical routine diagnostic (1,2).
- Its high reproducibility has been demonstrated in the prospective evaluation of an international quality assurance program (8).
- FEMTELLE™ is registered as a CE marked IVD product (in vitro diagnostic medical device).

Practical Details for uPA/PAI-1 testing:

- Keep excised tumor tissue on ice and transfer it to the pathological laboratory immediately.
- Upon diagnosis by a pathologist, a representative piece of tissue (50 – 200 mg) should be frozen.
- Store the frozen tissue until uPA/PAI-1 determination on dry ice or at -20°C.
- uPA / PAI-1 testing will be performed in different specialized laboratories.

Note: The test may not be performed on samples prepared from fixed tissue (e.g. formalin).

Please find selected scientific publications on reverse.

More information under: www.FEMTELLE.de
Selected Scientific Publications about:

„Prognostic value of uPA and PAI-1 in node-negative breast cancer“


For further information please contact:

Dr. Claudia Olenik
Product Manager
American Diagnostica GmbH
Kaplaneigasse 35
D- 64319 Pfungstadt

Tel: +49 (0) 6157 80 38 17
Fax: +49 (0) 6157 99 08 08
e-mail c.olenik@amdiag.de

www.FEMTELLE.de